Boehringer Ingelheim and Microsoft explore digital patient twins for clinical development

The new collaboration begins with lung health and brings disease modelling, trial simulation and workplace AI into a shared programme.

Boehringer Ingelheim and Microsoft announced a strategic collaboration on 22 October centred on AI-backed clinical development. Its first research focus is digital patient twins: computational representations that use clinical and related data to model how a disease and its outcomes may develop.

The partners will begin with lung health. They plan modelling, prototyping and evidence generation across disease and therapeutic areas, exploring disease progression, predictive outcomes and trial simulation. One research direction is the use of synthetic or hybrid control arms, drawing on existing data or combining it with a conventional control group.

Designing a more responsive trial process

A digital patient twin gives researchers a way to examine a proposed scenario before changing the design of a study. In the announced programme, the goal is to explore whether these models can help improve trial design, generate clinical evidence more efficiently and allow more participants to receive a new treatment.

The workflow connects several disciplines. Clinical teams define the question and relevant patient information. Modelling teams build the computational representation and examine how it behaves. Trial designers consider how the results could inform the next study. The partnership brings those activities into a shared research programme rather than presenting the model as a standalone clinical product.

AI across the organisation

The announcement also describes Boehringer Ingelheim's wider workforce programme. Building on its Microsoft Copilot deployment, the company is combining employee access with role-based use cases, skills development and governance. Security and datacentre modernisation form part of the collaboration, and the partners are considering further work in Animal Health, business processes and infrastructure.

This gives the partnership two connected tracks: a specialist scientific programme and an organisational foundation for people using AI across the business. The scientific work supplies domain-specific questions; the broader programme gives staff access, training and technology to take part.

For pharmaceutical teams, the interesting development is the way clinical modelling, employee capability and infrastructure are being planned together. AI adoption reaches from the individual research task to the operating environment that supports it.

Sources

- [Boehringer Ingelheim and Microsoft partner to drive patient-centric and AI-backed clinical development](https://news.microsoft.com/source/emea/2026/10/boehringer-ingelheim-and-microsoft-partner-to-drive-patient-centric-and-ai-backed-clinical-development/) — Microsoft · 2026-10-22